On Target Laboratories has closed its series B round at $44m after an $11.1m extension featuring Helsinn, following an initial tranche led by Johnson & Johnson in September.
US-based cancer detection technology developer On Target Laboratories closed a $44m series B round on Wednesday following an $11.1m extension from investors including pharmaceutical firm Helsinn.
Investment firm HIG BioHealth Partners and venture capital firm Elevate Ventures joined Helsinn in the extension.
Johnson & Johnson Innovation – JJDC, the corporate venturing subsidiary of healthcare group Johnson & Johnson, led the initial $32.5m tranche in September 2017, which also featured unnamed existing backers.
Spun out from Purdue University in 2010, On…